RRAD

Across TCGA pan-cancer cohorts, RRAD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RRAD data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RRAD mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RRAD expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where RRAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.718	0.960	.002	23	view →
LSCC	DFS	Quartile	All	0.816	1.000	.007	12	view →
PDAC	DFS	Median	II,III,IV	0.584	0.280	.015	11	view →
HNSC	DFS	Median	IV	0.815	0.567	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RRAD–CCRCC (OS)

Open the CCRCC breakdown →